The company has not filed an annual or quarterly report since its FY2019 10-K, filed Feb 27, 2020. Its latest SEC filing is a 15-12B from Apr 13, 2020.
10-K for FY2019, filed Feb 27, 2020
The sections below describe the company as of the FY2019 annual report.
Develops synthetic peptide drug candidates for people with serious complement-related diseases, including muscle and neurological conditions.
10-K for FY2019, filed Feb 27, 2020
The customer was Merck, under a direct drug-discovery collaboration: Ra provided technology rights and research, and Merck took responsibility for later development and commercialization.
10-K for FY2019, filed Feb 27, 2020
8-K, filed Apr 2, 2020
On April 2, 2020, Ra Pharmaceuticals, Inc., a Delaware corporation (the “Company”), completed its merger with Franq Merger Sub, Inc.…View ↗
Lead candidate disease focus
The lead program shifted from a candidate for paroxysmal nocturnal hemoglobinuria, refractory generalized myasthenia gravis and lupus nephritis to zilucoplan for generalized myasthenia gravis, immune-mediated necrotizing myopathy and amyotrophic lateral sclerosis.
10-K for FY2016, filed Mar 6, 2017 10-K for FY2019, filed Feb 27, 2020We are a clinical-stage biopharmaceutical company using our proprietary peptide chemistry platform to develop novel therapeutics for the…View ↗
We are developing our lead product candidate, zilucoplan, for the treatment of various complement-mediated diseases, including generalized…View ↗
Competes with Alexion Pharmaceuticals, argenx, UCB, Momenta, Immunovant, Takeda, Viela, Sanofi, Mitsubishi Tanabe Pharma America, Collaborative, Amylyx, Medicinova, AB Science, BioElectron, Orphazyme, Biohaven, Brainstorm, Revalesio, Prilenia, and Implicit
10-K for FY2019, filed Feb 27, 2020gMG. gMG is currently treated with cholinesterase inhibitors and nonspecific immunomodulatory or immunosuppressive agents most of which are…View ↗
Loading...
